← Back to All US Stocks

Cross Country Healthcare Inc. (CCRN) Stock Fundamental Analysis & AI Rating 2026

CCRN Nasdaq Services-Help Supply Services DE CIK: 0001141103
Updated This Month • Analysis: Mar 22, 2026 • SEC Data: 2025-12-31
Combined AI Rating
SELL
80% Confidence
STRONG AGREEMENT
SELL
78% Conf
SELL
82% Conf

📊 CCRN Key Takeaways

Revenue: $1.1B
Net Margin: -9.0%
Free Cash Flow: $40.1M
Current Ratio: 3.78x
Debt/Equity: 0.00x
EPS: $-2.93
AI Rating: SELL with 78% confidence
Cross Country Healthcare Inc. (CCRN) receives a SELL rating with 80% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $1.1B, net profit margin of -9.0%, and return on equity (ROE) of -29.4%, Cross Country Healthcare Inc. demonstrates mixed fundamentals in the Services sector. Below is our complete CCRN stock analysis for 2026.

Is Cross Country Healthcare Inc. (CCRN) a Good Investment?

Claude

Cross Country Healthcare faces severe operational distress with massive revenue contraction of 21.6% YoY and deteriorating profitability, including a net loss of $94.9M and negative operating income of $84.4M. While the company maintains adequate liquidity with a 3.78x current ratio and zero long-term debt, operational performance has dramatically worsened and is unsustainable without significant turnaround efforts.

ChatGPT

Cross Country Healthcare's fundamentals show a materially weakened earnings profile, with revenue down 21.6% year over year and margins deeply negative, indicating that the business is currently struggling to convert scale into profitability. While the balance sheet is strong with substantial cash, no long-term debt, and positive free cash flow, those strengths mainly provide stability rather than evidence of healthy operating momentum.

Why Buy Cross Country Healthcare Inc. Stock? CCRN Key Strengths

Claude
  • + Strong liquidity position with $108.7M cash and 3.78x current ratio
  • + Zero long-term debt provides financial flexibility
  • + Positive free cash flow of $40.1M despite operational losses
  • + Substantial asset base of $449M to support restructuring
ChatGPT
  • + Strong liquidity with a 3.78x current and quick ratio
  • + Debt-free balance sheet with $108.74M in cash and no long-term debt
  • + Positive operating cash flow and free cash flow despite net losses

CCRN Stock Risks: Cross Country Healthcare Inc. Investment Risks

Claude
  • ! Revenue declined 21.6% YoY with operating income of -$84.4M indicating severe business headwinds
  • ! Net margin of -9.0% and negative ROE of -29.4% show the business is destroying shareholder value
  • ! Gross margin of only 4.6% provides minimal buffer for operational expenses and leaves no room for error
  • ! Operating losses despite positive FCF suggest unsustainable accounting quality and potential working capital management concerns
ChatGPT
  • ! Sharp revenue contraction suggests weak demand or pricing pressure
  • ! Negative operating and net margins indicate severe profitability deterioration
  • ! Large net loss and negative returns on assets and equity raise concerns about earnings quality and capital efficiency

Key Metrics to Watch

Claude
  • * Revenue stabilization and return to growth trajectory
  • * Operating margin improvement back to positive territory
  • * Gross margin expansion to sustainable levels above 10%
  • * Return on equity recovery above 5%
ChatGPT
  • * Revenue trend and gross margin recovery
  • * Operating cash flow relative to net income and operating margin

Cross Country Healthcare Inc. (CCRN) Financial Metrics & Key Ratios

Revenue
$1.1B
Net Income
$-94.9M
EPS (Diluted)
$-2.93
Free Cash Flow
$40.1M
Total Assets
$449.0M
Cash Position
$108.7M

💡 AI Analyst Insight

The relatively thin 3.8% FCF margin may limit capital allocation flexibility. Strong liquidity with a 3.78x current ratio provides a solid financial cushion.

CCRN Profit Margin, ROE & Profitability Analysis

Gross Margin 4.6%
Operating Margin -8.0%
Net Margin -9.0%
ROE -29.4%
ROA -21.1%
FCF Margin 3.8%

CCRN vs Services Sector: How Cross Country Healthcare Inc. Compares

How Cross Country Healthcare Inc. compares to Services sector averages

Net Margin
CCRN -9.0%
vs
Sector Avg 10.0%
CCRN Sector
ROE
CCRN -29.4%
vs
Sector Avg 16.0%
CCRN Sector
Current Ratio
CCRN 3.8x
vs
Sector Avg 1.5x
CCRN Sector
Debt/Equity
CCRN 0.0x
vs
Sector Avg 0.7x
CCRN Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Cross Country Healthcare Inc. Stock Overvalued? CCRN Valuation Analysis 2026

Based on fundamental analysis, Cross Country Healthcare Inc. has mixed fundamental signals relative to the Services sector in 2026.

Return on Equity
-29.4%
Sector avg: 16%
Net Profit Margin
-9.0%
Sector avg: 10%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.7x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Cross Country Healthcare Inc. Balance Sheet: CCRN Debt, Cash & Liquidity

Current Ratio
3.78x
Quick Ratio
3.78x
Debt/Equity
0.00x
Debt/Assets
28.1%
Interest Coverage
-182.71x
Long-term Debt
$0.0

CCRN Revenue & Earnings Growth: 5-Year Financial Trend

CCRN 5-year financial data: Year 2021: Revenue $1.7B, Net Income -$57.7M, EPS $-1.61. Year 2022: Revenue $2.8B, Net Income -$13.0M, EPS $-0.36. Year 2023: Revenue $2.8B, Net Income $132.0M, EPS $3.53. Year 2024: Revenue $2.8B, Net Income $186.0M, EPS $4.95. Year 2025: Revenue $2.0B, Net Income $72.6M, EPS $2.05.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Cross Country Healthcare Inc.'s revenue has grown significantly by 20% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.05 reflects profitable operations.

CCRN Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
3.8%
Free cash flow / Revenue

CCRN Quarterly Earnings & Performance

Quarterly financial performance data for Cross Country Healthcare Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $250.1M $2.6M $0.08
Q2 2025 $274.1M -$6.7M $-0.20
Q1 2025 $293.4M -$490.0K $-0.02
Q3 2024 $315.1M $2.6M $0.08
Q2 2024 $339.8M -$13.4M $-0.39
Q1 2024 $379.2M $2.7M $0.08
Q3 2023 $442.3M $12.8M $0.36
Q2 2023 $540.7M $21.3M $0.60

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Cross Country Healthcare Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
$48.3M
Cash generated from operations
Stock Buybacks
$6.8M
Shares repurchased (TTM)
Capital Expenditures
$8.2M
Investment in assets
Dividends
None
No dividend program

CCRN SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Cross Country Healthcare Inc. (CIK: 0001141103)

📋 Recent SEC Filings

Date Form Document Action
Apr 2, 2026 4 xslF345X06/form4.xml View →
Apr 2, 2026 4 xslF345X06/form4.xml View →
Apr 2, 2026 4 xslF345X06/form4.xml View →
Apr 2, 2026 4 xslF345X06/form4.xml View →
Apr 2, 2026 4 xslF345X06/form4.xml View →

Frequently Asked Questions about CCRN

What is the AI rating for CCRN?

Cross Country Healthcare Inc. (CCRN) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are CCRN's key strengths?

Claude: Strong liquidity position with $108.7M cash and 3.78x current ratio. Zero long-term debt provides financial flexibility. ChatGPT: Strong liquidity with a 3.78x current and quick ratio. Debt-free balance sheet with $108.74M in cash and no long-term debt.

What are the risks of investing in CCRN?

Claude: Revenue declined 21.6% YoY with operating income of -$84.4M indicating severe business headwinds. Net margin of -9.0% and negative ROE of -29.4% show the business is destroying shareholder value. ChatGPT: Sharp revenue contraction suggests weak demand or pricing pressure. Negative operating and net margins indicate severe profitability deterioration.

What is CCRN's revenue and growth?

Cross Country Healthcare Inc. reported revenue of $1.1B.

Does CCRN pay dividends?

Cross Country Healthcare Inc. does not currently pay dividends.

Where can I find CCRN SEC filings?

Official SEC filings for Cross Country Healthcare Inc. (CIK: 0001141103) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is CCRN's EPS?

Cross Country Healthcare Inc. has a diluted EPS of $-2.93.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is CCRN a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Cross Country Healthcare Inc. has a SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is CCRN stock overvalued or undervalued?

Valuation metrics for CCRN: ROE of -29.4% (sector avg: 16%), net margin of -9.0% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.

Should I buy CCRN stock in 2026?

Our dual AI analysis gives Cross Country Healthcare Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is CCRN's free cash flow?

Cross Country Healthcare Inc.'s operating cash flow is $48.3M, with capital expenditures of $8.2M. FCF margin is 3.8%.

How does CCRN compare to other Services stocks?

Vs Services sector averages: Net margin -9.0% (avg: 10%), ROE -29.4% (avg: 16%), current ratio 3.78 (avg: 1.5).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 22, 2026 | Data as of: 2025-12-31 | Powered by Claude AI